Detection of *Mycoplasma genitalium*- Reactive Cervicovaginal Antibodies among Infected Women

Stefanie L. Iverson-Cabral,1,2* Lisa E. Manhart,3 and Patricia A. Totten1,2

Departments of Global Health, Pathobiology Interdisciplinary Program,1 Medicine, Division of Infectious Diseases,2 and Epidemiology,3 University of Washington, Seattle, Washington

Received 27 May 2011/Returned for modification 20 June 2011/Accepted 26 July 2011

*Mycoplasma genitalium*-reactive cervicovaginal IgA and IgG antibodies were detected in 51.9% and 70.4% of 27 infected women and 22.2% and 18.5% of 27 uninfected controls, respectively. The predominance of MgpB- and MgpC-reactive antibodies at the site of infection is consistent with their hypothesized role in selecting antigenic variants during persistent infection.

*Mycoplasma genitalium* is a sexually transmitted pathogen associated with urethritis in men and various inflammatory conditions in women, including cervicitis (reviewed in references 10 and 20). Additionally, *M. genitalium* is associated with chronic infection, as highlighted by retrospective longitudinal studies of urethritis (7) and cervicitis (3). Such persistence may aggravate the risk of adverse reproductive outcomes, including tubal-factor infertility and preterm birth, conditions associated with this organism (2, 6, 18). Circulating antibodies have been detected in the serum of men with *M. genitalium*-associated urethritis (19) and women with tubal-factor infertility (2, 18); however, the local antibody response in the lower genital tract remains uncharacterized. To better understand the immunopathogenesis of *M. genitalium*, we investigated the cervicovaginal antibody response at the initial site of infection.

To detect *M. genitalium*-reactive antibodies in the lower genital tract by immunoblotting, we used cervical and vaginal samples. These specimens were originally collected in our clinic; Sigma-Aldrich), each diluted 1:10,000. Additionally, samples were reacted against lysates of *M. genitalium* mutants (1). The lysate (100 μg protein) was separated by electrophoresis using a single-well 7.5% SDS-polyacrylamide gel, and then proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Invitrogen). Membranes were incubated overnight (4°C) in blocking/dilution buffer (5% nonfat milk in PBS-0.1% Tween 20), cut into 5-mm strips, and reacted for 1 h with a 1:50 dilution of the cervical or vaginal specimen (swabs rehydrated in 2-sucrose-phosphate-based transport medium [c2SP]) (22). Membranes were washed (PBS-0.1% Tween 20) and incubated for another hour with peroxidase-conjugated goat anti-human IgG (whole molecule; Sigma-Aldrich, St. Louis, MO), IgA (alpha-chain; Sigma-Aldrich), or IgM (mu-chain; Sigma-Aldrich) diluted 1:10,000 or peroxidase-conjugated mouse anti-human IgG1, IgG2, IgG3, or IgG4 (Invitrogen) diluted 1:500. After another wash, membranes were developed with the Amersham ECL kit (GE Healthcare, Buckinghamshire, United Kingdom) and exposed to Kodak BioMax XAR film (Carestream Health, Rochester, NY); the appearance of bands after 20 min of exposure was interpreted as a positive result. To identify MgpB and MgpC, sera from rabbits immunized with His-tagged recombinant peptides made from fragments of either protein (S. L. Iverson-Cabral and P. A. Totten, unpublished data) were used with peroxidase-conjugated goat anti-rabbit IgG (whole molecule; Sigma-Aldrich), each diluted 1:10,000. Additionally, samples were reacted against lysates of *mgpB* and *mgpC* deletion mutants (1).

**TABLE 1. Cervicovaginal immune response to *M. genitalium* among cases and controls**

| Immunoglobulin isotype | Sample site | Cases | Controls | P value* |
|------------------------|-------------|-------|----------|----------|
|                        | Cervix      | 19 (70.4) | 4 (14.8) | <0.001   |
|                        | Vagina      | 12 (44.4) | 3 (11.1) | 0.014    |
|                        | Either site | 19 (70.4) | 5 (18.5) | <0.001   |
| IgA                    | Cervix      | 14 (51.9) | 6 (22.2) | 0.047    |
|                        | Vagina      | 9 (33.3)  | 0 (0.0)  | 0.002    |
|                        | Either site | 14 (51.9) | 6 (22.2) | 0.047    |

*Women with *M. genitalium* DNA detected in both urine and vagina by TMA.

*Women who were TMA-negative for *M. genitalium* DNA in the urine and vagina.

*P values calculated by Fisher's exact two-tailed test.

**TABLE 2. Distribution of *Mycoplasma genitalium*-reactive cervicovaginal IgA and IgG antibodies among cases and controls**

![Image](https://via.placeholder.com/150)

* Corresponding author. Mailing address: Department of Medicine, Harborview Medical Center R&T Building, 325 9th Avenue, Box 359779, Seattle, WA 98104. Phone: (206) 897-5354. Fax: (206) 897-5363. E-mail: slic@u.washington.edu.

* Published ahead of print on 3 August 2011.
Infected women exhibited a cervicovaginal anti-\textit{M. genitalium} response. \textit{M. genitalium}-positive women were more likely to exhibit \textit{M. genitalium}-reactive IgG and IgA than uninfected controls ($P_{\text{H11005}} = 0.001$ and 0.047, respectively) (Table 1). While we were unable to identify \textit{M. genitalium}-reactive IgM in cases or controls (data not shown), the IgG and IgA responses were pronounced (Fig. 1). The concordance for these isotypes among cases was relatively high, with both IgG and IgA detected in 74% and 50% of immunoblot-positive cervical and vaginal samples, respectively. To characterize the IgG response further, we isotyped a subset of the strongly IgG-positive specimens for which adequate sample volume was available: 11 (57.9%) and 7 (36.8%) of the 19 cervical and 3 (37.5%) and 1 (12.5%) of the eight vaginal samples tested were positive for IgG1 and IgG3, respectively (Fig. 2). Beyond the nonspecific binding of the IgG2 secondary antibody (Fig. 2), there was no evidence of an IgG2 or IgG4 response.

Although various \textit{M. genitalium} proteins were antigenic (Fig. 1), antibodies against the 140-kDa MgpB and 110-kDa MgpC proteins were predominantly detected. These observations are consistent with previous immunologic studies of circulating antibodies in \textit{M. genitalium}-infected individuals (2, 18, 19). Immunoblotting against lysates of \textit{mgpB} and \textit{mgpC} deletion mutants confirmed that these antigens were indeed MgpB and MgpC (Fig. 3). Among all immunoblot-positive women (including cases and controls), 92.3% (24/26) and 69.2% (18/26) had antibodies that recognized MgpB and MgpC, respectively; in fact, only two cervical samples from control women failed to react with MgpB and instead contained antibodies that targeted other, unknown \textit{M. genitalium} antigens (participants 108 and 182) (Fig. 1). More detailed data regarding the antigenicity of MgpB and MgpC by sample site and antibody isotype are shown in Fig. 4.

To our knowledge, this is the first documentation of the...
antibody response to M. genitalium in the lower genital tract. Our observations indicate that M. genitalium infection elicits a cervicovaginal IgA and IgG response, including IgG1 and IgG3 subtypes, with the MgpB and MgpC proteins immunogenic. Furthermore, the association between M. genitalium infection and the detection of IgG and IgA was significant. Differences in antibody response among infected women may reflect the site or duration of infection, previous exposure to this pathogen, or hormonal influences (12). The reactivity of some control specimens is likely due to prior M. genitalium infection or to nonspecific or cross-reactive antibodies, as likely observed with participants 108 and 182 (Fig. 2).

The biologic activity of M. genitalium-specific antibodies remains unknown. The isotypes identified in this study suggest that cervicovaginal antibodies may be involved in attachment-inhibition, complement-mediated killing, and/or opsonophagocytosis. IgG and IgA play an important role in mucosal defense and have different effector functions that work in concert to protect the host from infection. IgA serves as a first line of defense by preventing binding (17), interfering with motility, and enhancing opsonization through agglutination (21). The dominant isotype in cervicovaginal secretions is IgG (12, 14). Of the four isotypes, IgG1 and IgG3 are the most biologically active and proinflammatory through complement activation (15). These subtypes help control bacterial infections with opsonization and enhanced phagocytosis via the Fc receptor (4).

In contrast, IgG4 lacks such effector functions (16), and IgG2 has low levels of complement activation (17), which is interesting given our negative results with these subtypes. We also failed to detect an IgM response, which may be explained by the low levels of IgM in genital secretions (14). Alternatively, these observations could be influenced by the timing of sample collection in the course of infection, as IgM is a short-lived isotype typically produced early in infection (17). Testing specimens collected closer to the onset of infection or selectively removing potentially interfering IgG from the sample may allow the detection of cervicovaginal IgM antibodies in future experiments.

Despite the induction of an antibody response at the initial site of infection, M. genitalium persists (3, 7), suggesting that this organism may have a mechanism(s) of immune evasion. It is noteworthy that the dominant antigens, MgpB and MgpC, are encoded by genes that exhibit extensive sequence diversity. Portions of mgpB and mgpC vary over time within M. genitalium G37 cultured in vitro and in samples collected longitudinally from individuals chronically infected with a single strain (8, 9, 13). We hypothesize that the evolution of sequence heterogeneity corresponds to changes in MgpB and MgpC antigenicity, allowing bacteria to escape the biologic activity of antibodies elicited by infection. Future studies are needed to characterize the biologic role of M. genitalium-specific antibodies and to correlate the development of antigenic diversity with the induction of these antibodies.

(These data were presented, in part, at the 108th General Meeting of the American Society for Microbiology, Boston, MA, 1 to 5 June 2008.)

This study was supported by grants R01 AI/4634, R56 AI07115, and NIH U19 AI31448 and the University of Washington STD/AIDS Research Training Grant NIH/HAIID T32 AI7140-33 (S.L.I.). We thank Anna Wald, Gwen Wood, and Raul Burgos for critical reading of the manuscript, Laura DeMaster for assisting in preliminary experiments, and Jaume Pínol for providing us with the deletion mutant strains.

REFERENCES
1. Burgos, R., et al. 2006. Mycoplasma genitalium P140 and P110 cytadhesins are reciprocally stabilized and required for cell adhesion and terminal-organelle development. J. Bacteriol. 188:8627–8637.
2. Clausen, H. F., et al. 2001. Serological investigation of Mycoplasma genitalium in infertile women. Hum. Reprod. 16:1866–1874.
3. Cohen, C. R., et al. 2007. Mycoplasma genitalium infection and persistence in a cohort of female sex workers in Nairobi, Kenya. Sex. Transm. Dis. 34:274–279.
4. Hamilton, R. G. 1987. Human IgG subclass measurements in the clinical laboratory. Clin. Chem. 33:1707–1725.
5. Hancock, E. R., et al. 2010. Comprehensive assessment of sociodemographic and behavioral risk factors for Mycoplasma genitalium infection in women. Sex. Transm. Dis. 37:777–783.
6. Hitti, J., et al. 2010. Correlates of cervical Mycoplasma genitalium and risk of preterm birth among Peruvian women. Sex. Transm. Dis. 37:81–85.
7. Horner, P., B. Thomas, C. B. Gilroy, M. Egger, and D. Taylor-Robinson. 2001. Role of Mycoplasma genitalium and Ureaplasma urealyticum in acute and chronic nongonococcal urethritis. Clin. Infect. Dis. 32:995–1003.
8. Iverson-Cabral, S. L., S. G. Astete, C. R. Cohen, E. P. Rocha, and P. A. Totten. 2006. Intrastrain heterogeneity of the mgpB gene in Mycoplasma genitalium is extensive in vitro and in vivo and suggests that variation is generated via recombination with repetitive chromosomal sequences. Infect. Immun. 74:3715–3726.
9. Iverson-Cabral, S. L., S. G. Astete, C. R. Cohen, and P. A. Totten. 2007. mgpB and mgpC sequence diversity in Mycoplasma genitalium is generated by segmental reciprocal recombination with repetitive chromosomal sequences. Mol. Microbiol. 66:55–73.
10. Jensen, J. S. 2004. Mycoplasma genitalium: the aetiological agent of urethritis and other sexually transmitted diseases. J. Eur. Acad. Dermatol. Venereol. 18:1–11.
11. Kenny, G. E. 1985. Mycoplasmas, p. 407–411. In E. H. Lennette, A. Balows, W. J. Hausler, Jr., and H. J. Shadomy (ed.), Manual of clinical microbiology, 4th ed. American Society for Microbiology, Washington, DC.
12. Kutteh, W. H., S. J. Prince, K. R. Hammond, C. C. Kutteh, and J. Mestecky. 1996. Variations in immunoglobulin and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin. Exp. Immunol. 104:538–542.
13. Ma, L., et al. 2007. Mycoplasma genitalium: an efficient strategy to generate genetic variation from a minimal genome. Mol. Microbiol. 66:220–236.
14. Mestecky, J., R. C. Alexander, Q. Wei, and Z. Moldoveanu. 2011. Methods for evaluation of humoral immune responses in human genital tract secretions. Am. J. Reprod. Immunol. 65:361–367.
15. Mestecky, J., M. Raska, J. Novak, R. C. Alexander, and Z. Moldoveanu. 2010. Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design. J. Reprod. Immunol. 85:81–85.
16. Nirula, A., S. M. Glasier, S. L. Kalled, and F. R. Taylor. 2011. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr. Opin. Rheumatol. 23:119–124.
17. Schroeder, H. W., Jr., and L. Cavacini. 2010. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125:S41–S52.
18. Svenstrup, H. F., et al. 2008. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility—a prospective study. Fertil. Steril. 90:513–520.
19. Svenstrup, H. F., J. S. Jensen, K. Gevaert, S. Birkelund, and G. Christiansen. 2006. Identification and characterization of immunogenic proteins of Mycoplasma genitalium. Clin. Vaccine Immunol. 13:913–922.
20. Totten, P., D. Taylor-Robinson, and J. S. Jensen. 2006. Genital mycoplasmas, p. 709–736. In P. S. K. Holmes, W. Stamm, J. Wasserheit, L. Corey, M. Cohen, and H. Watts (ed.), Sexually transmitted diseases, 4th ed. McGraw-Hill, New York, NY.
21. van Egmond, M., et al. 2001. IgA and the IgA Fc receptor. Trends Immunol. 22:205–211.
22. Wroblewski, J. K., L. E. Manhart, K. A. Dickey, M. K. Hudspeth, and P. A. Totten. 2006. Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium. J. Clin. Microbiol. 44:3306–3312.